LyondellBasell
LYB
$73.04
-1.47%
LyondellBasell Industries N.V. is a global petrochemical producer, operating in the Basic Materials sector within the Specialty Chemicals industry. The company is the world's largest producer of polypropylene and a major manufacturer of polyethylene and propylene oxide, with its chemicals serving a wide array of consumer and industrial end products. As a market leader with a significant North American production footprint, the company's current investor narrative is dominated by navigating a severe industry downturn, as evidenced by its recent dividend cut, while simultaneously grappling with volatile input costs and supply chain disruptions stemming from geopolitical tensions in the Middle East.…
LYB
LyondellBasell
$73.04
Related headlines
Investment Opinion: Should I buy LYB Today?
Rating & Thesis: Hold. LYB presents a high-risk, high-reward proposition at a critical cyclical inflection point, but the current price fairly balances the deep valuation discount against severe near-term fundamental headwinds, aligning with the neutral analyst consensus and average target implying slight downside.
Supporting Evidence: The primary valuation metric, the trailing PS ratio of 0.46, is exceptionally low and suggests significant pessimism is priced in. However, this is justified by a -25.33% YoY revenue decline and negative trailing net margin of -2.46%. The forward PE of 10.16 indicates the market expects a return to profitability, but this hinges on a gross margin recovery from 6.49%. The stock's 6-month surge of +65.70% has likely front-run much of the near-term recovery potential, leaving limited margin of safety.
Risks & Conditions: The two biggest risks are a further prolongation of the chemical downturn, delaying the margin recovery, and a breakdown in technical support near $70, which could trigger a deeper correction. This Hold rating would upgrade to a Buy if the PS ratio falls further below 0.4 on sustained negative sentiment, or if Q1 2026 results show clear sequential improvement in gross margins. It would downgrade to a Sell if revenue growth fails to stabilize or turns more negative, or if the stock breaks below key support at $65. The stock is currently fairly valued relative to its depressed fundamentals but undervalued relative to a normalized cycle, making timing the entry critical.
Sign up to view all
LYB 12-Month Price Forecast
LYB is a battleground stock caught between compelling cyclical value and harsh current realities. The neutral stance reflects the high probability (50%) of a slow, grinding base-case recovery where the stock churns. The substantial cash flow is a critical mitigating factor, but the recent dividend cut and negative earnings create near-term headwinds that the +65% rally seems to overlook. Confidence is medium due to the wide dispersion of analyst targets and high macro/cycle dependency. The stance would upgrade to bullish on confirmation of margin stabilization (e.g., gross margin >8% for two consecutive quarters) and downgrade to bearish on a breakdown below $65 support, which would signal a failure of the recovery narrative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $94.95 and implied upside of +30.0% versus the current price.
Average Target
$94.95
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$58 - $95
Analyst target range
The stock is covered by 10 analysts, and recent institutional rating actions show a mixed but generally neutral-to-cautious sentiment, with firms like Wells Fargo and Deutsche Bank maintaining 'Equal Weight' and 'Hold' ratings, respectively, while Citigroup and RBC Capital have recently upgraded to 'Buy' and 'Outperform'. The consensus recommendation leans neutral, with the average target price implied by estimated EPS and the forward PE ratio being approximately $73.45, which suggests a slight downside of about -2.1% from the current price of $75.06. The target range, derived from EPS estimates, is wide, with a low target around $46.50 (based on low EPS of $4.58) and a high target near $98.10 (based on high EPS of $9.66), indicating significant uncertainty among analysts regarding the pace and magnitude of earnings recovery. The low target likely prices in a prolonged downturn with continued margin pressure, while the high target assumes a robust cyclical recovery and multiple expansion. The recent dividend cut and geopolitical supply shocks contribute to this wide dispersion, signaling low near-term conviction and high fundamental uncertainty surrounding the stock's outlook.
Bulls vs Bears: LYB Investment Factors
The investment debate for LYB is a classic clash between cyclical valuation and deteriorating fundamentals. The bull case, currently supported by stronger evidence from price action and valuation extremes, hinges on the belief that the stock has already priced in a worst-case scenario and that the robust $2.26B in annual FCF provides a durable bridge to recovery. The bear case is grounded in the harsh reality of a -25% revenue decline, a dividend cut, and negative profitability, questioning the sustainability of the recent rally. The single most important tension is the timing of the cyclical inflection in chemical demand and margins. If signs of stabilization emerge in the next quarter or two, the deep PS discount of 0.46 could drive significant multiple expansion. However, if the downturn persists longer than anticipated, the current price level appears vulnerable to a fundamental re-rating lower.
Bullish
- Strong Cash Flow Despite Downturn: The company generated $2.262 billion in trailing twelve-month free cash flow, providing a significant buffer to weather the cyclical trough. This robust cash generation supports the reduced dividend and provides financial flexibility for strategic moves or debt management.
- Deep Cyclical Valuation Discount: LYB trades at a trailing Price-to-Sales ratio of 0.46, near the bottom of its historical range and well below the 1.97 seen just a quarter ago. This extreme discount suggests the market has priced in a severe and prolonged downturn, leaving substantial room for multiple expansion on any signs of recovery.
- Powerful Technical Uptrend: The stock has surged 65.70% over the past six months and is trading at 89% of its 52-week high, indicating strong investor momentum and a belief in an impending cyclical recovery. The low beta of 0.355 suggests this rally has been unusually stable for a cyclical stock, potentially attracting more conservative capital.
- Analyst Upgrades Amid Uncertainty: Despite a wide target range, recent institutional actions include upgrades to 'Buy' and 'Outperform' from Citigroup and RBC Capital. The high analyst target of $98.10, based on an EPS estimate of $9.66, implies a 31% upside and reflects a credible bull case for a sharp earnings recovery.
Bearish
- Severe Fundamental Deterioration: Q4 2025 revenue declined 25.33% YoY to $7.091B, and the company posted a net loss of -$140M with a net margin of -2.46%. Gross margins collapsed to 6.49% from 15.12% in Q3 2024, indicating acute pricing pressure and weak demand across the chemical cycle.
- Dividend Cut Signals Prolonged Pain: The company recently slashed its dividend, a move explicitly linked by management to 'one of the longest downturns in the chemical industry.' This action erodes a key pillar of the investment thesis for income-oriented shareholders and signals management's expectation of sustained cash flow challenges.
- Analyst Consensus Suggests Downside: The consensus analyst target price implied by estimated EPS and the forward PE is approximately $73.45, representing a -2.1% downside from the current price of $75.06. The neutral consensus rating and wide target range ($46.50 to $98.10) reflect low near-term conviction and high fundamental uncertainty.
- Valuation Disconnect with Fundamentals: The stock's powerful 6-month rally of +65.70% has occurred alongside deteriorating financials, creating a disconnect. The forward PE of 10.16 assumes a return to profitability, but any delay in the earnings recovery could lead to a sharp correction from current elevated price levels.
LYB Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +28.48% and a remarkable 6-month surge of +65.70%. As of the latest close at $75.06, the price is trading near the top of its 52-week range, approximately 89% of the way from its low of $41.58 to its high of $83.94, indicating strong momentum but also potential overextension. Recent momentum shows a notable deceleration from the explosive 3-month gain of +30.29% to a more modest 1-month increase of +2.64%, suggesting the rally may be entering a consolidation phase or facing near-term resistance. This divergence is further highlighted by a negative 1-month relative strength of -2.96 against the SPY, indicating the stock has recently underperformed the broader market's rally. Key technical support is anchored at the 52-week low of $41.58, while immediate resistance sits at the 52-week high of $83.94; a decisive breakout above this level would signal a resumption of the primary uptrend, whereas a breakdown below the recent consolidation range near $70 could indicate a deeper pullback. The stock's low beta of 0.355 suggests it has been significantly less volatile than the market during this period, which is atypical for a cyclical materials stock in a strong trend and may imply a more defensive positioning by investors.
Beta
0.35
0.35x market volatility
Max Drawdown
-37.1%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+23.4%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | +10.2% | +3.3% |
| 3m | +30.5% | +6.9% |
| 6m | +71.7% | +12.4% |
| 1y | +23.4% | +23.4% |
| ytd | +64.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
Revenue trajectory is declining, with Q4 2025 revenue of $7.091 billion representing a -25.33% year-over-year contraction, continuing a trend of sequential quarterly declines from $7.677 billion in Q1 2025. Segment data indicates the Polyethylene segment was the largest contributor at $1.676 billion, but the overall decline signals broad-based demand weakness across the chemical cycle. The company is currently unprofitable, posting a Q4 2025 net income of -$140 million and a trailing net margin of -2.46%, with profitability having deteriorated sharply from a net income of $175 million in Q1 2025. Gross margins are severely compressed at 6.49% for Q4 2025, down from 7.15% in Q1 2025 and drastically below the 15.12% seen in Q3 2024, reflecting intense pressure from input costs and weak pricing power. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.58, but the company maintains a strong current ratio of 1.77, indicating good short-term liquidity. Crucially, the company continues to generate substantial cash, with trailing twelve-month free cash flow of $2.262 billion, providing a buffer to navigate the downturn, fund its reduced dividend, and maintain financial flexibility despite the earnings slump.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.46, which is exceptionally low and reflects the market's discounting of depressed margins within the cyclical trough. For context, the forward PE ratio is 10.16, indicating the market expects a return to profitability, but the gap with the negative trailing PE of -18.77 underscores the depth of the current earnings downturn. Compared to typical industry averages for chemical companies, a PS ratio below 0.5 represents a steep discount, often seen during severe cyclical lows or when significant margin erosion is priced in. This discount is justified by the company's current lack of profitability and compressed gross margins of 9.0%, but it may also present a value opportunity if the cycle inflects. Historically, the stock's own PS ratio has fluctuated widely, with the current 0.46 sitting near the bottom of its observable range, well below the 1.97 seen just a quarter prior in Q4 2025. Trading near historical valuation lows suggests the market has priced in a pessimistic scenario regarding the duration and depth of the chemical industry downturn, leaving room for multiple expansion on any signs of fundamental recovery.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on severe margin compression and earnings volatility. Gross margins have collapsed from 15.12% in Q3 2024 to 6.49% in Q4 2025, while the company swung to a -$140M net loss. Revenue has declined sequentially for three quarters, with a -25.33% YoY drop in Q4, indicating broad-based demand weakness. While the debt-to-equity ratio of 1.58 is moderate, the recent dividend cut underscores that cash preservation is a priority, and any prolongation of the downturn could pressure the balance sheet despite the strong current ratio of 1.77.
Market & Competitive Risks include valuation compression from current elevated technical levels. The stock trades at 89% of its 52-week high after a +65.7% 6-month rally, yet fundamentals are deteriorating. Its low beta of 0.355 is atypical and may not hold if the cycle worsens, leading to increased volatility. The company remains highly sensitive to volatile input costs, as evidenced by recent Middle East supply disruptions, and faces intense global competition in polyethylene and polypropylene, limiting pricing power during downturns.
Worst-Case Scenario involves a prolonged chemical industry slump combined with a resurgence of geopolitical supply shocks, leading to sustained margin pressure and further earnings misses. This could trigger analyst downgrades to the low target of $46.50, a re-test of the 52-week low of $41.58, and a loss of investor confidence in the recovery narrative. From the current price of $75.06, this scenario implies a potential downside of -38% to the analyst low target and -45% to the 52-week low, representing a severe drawdown consistent with the stock's historical max drawdown of -37.1%.
FAQ
The key risks are, in order of severity: 1) Cyclical/Pricing Risk: Prolonged industry downturn preventing gross margin recovery from the current 6.49%, leading to sustained losses. 2) Macro/Demand Risk: Sensitivity to global economic growth; a recession could deepen the revenue decline beyond the current -25% YoY. 3) Input Cost Volatility: Geopolitical events (like recent Middle East disruptions) can spike feedstock costs, squeezing margins further. 4) Capital Allocation Risk: The recent dividend cut signals financial stress; further cuts or a dilutive capital raise could erode shareholder confidence. The stock's low beta of 0.355 may not protect against these fundamental risks.
The 12-month forecast is highly bifurcated, with a 50% probability base case target range of $70-$85, a 30% probability bull case target of $90-$98, and a 20% probability bear case target of $46-$60. The wide dispersion reflects extreme uncertainty around the timing and strength of the chemical cycle recovery. The most likely scenario is a gradual, uneven recovery (base case) where the stock consolidates recent gains. The forecast hinges almost entirely on the trajectory of gross margins; stabilization and improvement above 8% would support the base case, while a drop below 5% would activate the bear case.
LYB is both undervalued on a normalized cycle basis and fairly valued given its current depressed fundamentals. The trailing Price-to-Sales ratio of 0.46 is near historical lows and represents a steep discount to the industry, implying the market expects severely depressed margins to persist. The forward PE of 10.16 suggests the market is paying a reasonable price for expected future earnings recovery. However, the recent +65.7% price surge has narrowed the discount, creating a disconnect. Overall, the stock is fairly valued at present, but deeply undervalued if one has high conviction in a cyclical earnings rebound over the next 18-24 months.
LYB is a speculative buy only for investors with a high risk tolerance and a long-term horizon who believe the chemical cycle is near its trough. At the current price of $75.06, it trades slightly above the analyst average target of ~$73.45, offering no immediate margin of safety. The compelling valuation (PS of 0.46) and strong cash flow ($2.26B TTM) are offset by severe fundamental deterioration, including a -25% revenue decline and a dividend cut. It could be a good buy on a significant pullback towards the $65-$70 range for those betting on a 2027 recovery, but it is not a good buy for conservative or income-focused investors.
LYB is strictly a long-term investment for a minimum holding period of 3-5 years to fully capture a potential chemical cycle upswing. It is unsuitable for short-term trading due to its high sensitivity to quarterly earnings volatility, macro sentiment, and commodity prices. The dividend cut removes the income component for shorter horizons. While the stock has shown strong momentum recently, this is characteristic of early-cycle moves that can reverse quickly on negative news. Patient investors can use periods of weakness to build a position, but must be prepared for significant volatility and a potentially long wait for the thesis to play out.
